Media headlines about Oramed Pharmaceuticals (NASDAQ:ORMP) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.5706567865892 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
NASDAQ:ORMP traded down $0.11 during trading hours on Friday, hitting $4.78. 75,601 shares of the stock were exchanged, compared to its average volume of 56,972. Oramed Pharmaceuticals has a 52-week low of $4.70 and a 52-week high of $11.34. The firm has a market cap of $84.90 million, a P/E ratio of -6.05 and a beta of 0.39.
Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings data on Thursday, July 12th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.03). Oramed Pharmaceuticals had a negative return on equity of 63.20% and a negative net margin of 204.00%. The firm had revenue of $0.62 million for the quarter, compared to analysts’ expectations of $0.61 million. analysts anticipate that Oramed Pharmaceuticals will post -0.92 earnings per share for the current year.
ORMP has been the subject of several research reports. HC Wainwright set a $25.00 price objective on Oramed Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, June 6th. ValuEngine upgraded Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 31st. Finally, B. Riley lowered Oramed Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, July 16th.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.
Featured Story: What do investors mean by earnings per share?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.